Key Highlights
- Third quarter net sales rose 10.4% to USD 7.86 billion, ahead of the USD 7.72 billion estimate.
- Adjusted EPS of USD 0.44 topped the USD 0.34 estimate, while GAAP diluted EPS was USD 0.22.
- Adjusted EBITDA rose 11.8% to USD 960 million, and Tariff refunds added a net USD 81 million.
- Organic sales guidance moved to 10.0% to 10.5%, and the board authorized a USD 1 billion buyback.
Medline Inc. (NASDAQ:MDLN) reported third quarter net sales of USD 7.86 billion, up 10.4% from USD 7.12 billion and above the USD 7.72 billion estimate. Adjusted diluted EPS of USD 0.44 exceeded the USD 0.34 estimate, while GAAP diluted EPS was USD 0.22. Net Income was USD 318 million, down 1.2% from USD 322 million, as higher inventory costs, operating expenses and customer mix offset the sales gain.
Sales Mix by Segment
Organic sales grew 10.5%, driven mainly by existing customer growth and the rollout of new customer signings from 2025. Chief executive Jim Boyle said the company posted double-digit sales growth and continued to progress toward its annual new customer signings goal.
The Supply Chain Solutions segment grew net sales 13.9% to USD 4.22 billion, but its adjusted EBITDA fell 10.2% to USD 184 million, and its Margin narrowed to 4.4% from 5.5%. The Medline Brand segment grew 6.6% to USD 3.64 billion, with adjusted EBITDA up 14.9% to USD 943 million and a margin of 25.9%, compared with 24.1% a year earlier.
Margins, Tariff Refunds and Cash
Gross profit rose 2.7% to USD 1.93 billion, and gross margin was 24.5%, down from 26.4%. Selling, general and administrative expenses grew 12.8% to USD 1.26 billion, and Operating Income fell 12.9% to USD 500 million. Interest expense dropped to USD 118 million from USD 213 million.
Adjusted EBITDA reached USD 960 million, a 12.2% margin compared with 12.1% a year earlier. Following the U.S. Supreme Court's February 2026 ruling that IEEPA tariffs were unauthorized, Medline recognized net refund benefits of USD 81 million in the quarter and USD 324 million over nine months, all within the Medline Brand segment.
For the nine months, net income fell 28.8% to USD 696 million, including net losses of USD 316 million tied to a fire at the Tracy, California distribution center. Operating Cash Flow was USD 2.15 billion and free cash flow was USD 1.8 billion after USD 348 million of capital expenditures.
Guidance and Capital Allocation
Medline raised its full year 2026 Organic Sales growth guidance to 10.0% to 10.5% from 9.0% to 10.0%. It reaffirmed adjusted EBITDA guidance of USD 3.3 billion to USD 3.4 billion, which excludes tariff refunds. In October, the board authorized repurchases of up to USD 1 billion of Class A common stock and units of Medline Holdings, LP, and the company prepaid USD 750 million of its 2033 refinancing term loan.
At quarter end, cash and equivalents were USD 2.32 billion, with another USD 1.29 billion in short-term investments. Total Debt was USD 12.74 billion, resulting in net debt of USD 9.14 billion and net Leverage of 2.5 times trailing adjusted EBITDA of USD 3.60 billion.
Reference Points for Investors
Adjusted EPS of USD 0.44 compares with GAAP EPS of USD 0.22, while nine month adjusted EPS of USD 1.27 compares with GAAP EPS of USD 0.45. Third quarter organic sales growth of 10.5% sits against the 10.0% to 10.5% full year guide. Net debt of USD 9.14 billion compares with the USD 1 billion repurchase authorization and the USD 750 million Loan prepayment.
Adjusted EBITDA of USD 2.80 billion over nine months compares with the USD 3.3 billion to USD 3.4 billion full year guide, which leaves roughly USD 0.5 billion to USD 0.6 billion for the fourth quarter by simple subtraction.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...